Expanded On Demand Programme

Session I: Cancer of the Pancreas and Biliary Tract

Hereditary Pancreatic Cancer: Genetics & Surveillance

Targeting the Microenvironment and the Immune System

How to Integrate and Interpret Best Imaging in Locally Advanced PDAC and What to Use for Response Evaluation: EUS, PET/CT, MRI

Debate: Neoadjuvant Treatment for Resectable Pancreatic Cancer. Yes vs. No

Treatment Modalities for Locally Advanced Pancreatic Cancer (including SBRT, ablation,)

The Actual Algorithm in Advanced PDAC: A Strategic Approach (covering later lines, PARP)   

Druggable Molecular Alterations in Bile Duct Cancer

Locally Advanced Bile Duct Cancer

 

Session II: Progress in GI Cancer

How can Consortia contribute to the Progress in GI Oncology? Contribution of the ARCAD group

How can Consortia contribute to the Progress in GI Oncology? Contribution of the ACCENT group

Teaching and Interpreting Statistics for Clinicians

Reporting on Endpoints: The Example in CRC

 

Session III: Esophageal and Gastric Cancers

When and How to Treat Early Esophageal Cancer Endoscopically (covering EMR, ESD, RFA)

Debate: GEJ Cancer: Locally Advanced Perioperative CT or Preoperative CRT. Pro Chemo vs. Pro Neoadjuvant CRT

Adjuvant Treatment After Preoperative CRT in Esophageal or GEJ Cancer: When and How?

Interaction Between Neoadjuvant Therapies, Comorbidity and Surgery

 

Session IV: Gastric Cancer

Treatment Algorithms in Metastatic Gastric Cancer

New HER2-Directed Agents in Gastric Cancer

 

Session V: Impact of Patient Factors in Disease Biology in GI Cancer: Gender and Age

The Explosion of CRC (or GI Cancer) in Young Adults: Why?

Why Does Gender Matter for Treatment?

 

Session VI: Relevant Pathways in GI Cancer: How Relevant and How to Approach Them

The HER2 Pathway in GI Cancer

FGFR and Other Fusions in GI Cancer

Should DPD Deficiency be Tested Before Starting 5FU?

How to Interpret an NGS Sequencing Report?

Tumor or Liquid Biopsies in the Future? Pro Tumor vs. Liquid Biopsies; Discussion

 

Session VII: Keynote Presentations

Keynote Lecture: Integrating Health Economic Evaluation into Daily Practice in the COVID-19 Era

Keynote Lecture: New Promising PET Tracers

 

Session VIII: Hepatocellular Cancer

Can We Maximize the Benefit of IO in HCC

Locoregional Treatment in HCC

Liver Transplantation in the COVID-19 Era

 

Session IX: Multimodality Therapy for Rectal Cancer

Neoadjuvant Treatment: How and for Whom?

Organ Preserving Strategy

Local excision (TEM/TAM) vs Radical Resection – When and in Whom?

Case Presentations

 

Session X: Immune Mechanisms and Immune Therapy in GI Cancer

Biomarkers for Checkpoint Inhibitors in GI cancer

How Can We Increase the Immunogenicity in MSS CRC?

The Link Between the Immune Microenvironment and Outcomes in Colorectal Cancer

New immunotherapy combinations (anti VEGF + CPi; CART; TKIs + CPi) in GI cancers

 

Session XI: Molecular Biology in Colorectal Cancer

Liver Transplantation in GI Cancer: A Reality or An Illusion? The Case in NET, Cholangiocarcinoma, and CRC

Genetic Risk Factors for GI Cancers/Hereditary Syndromes

 

Session XII: Colorectal Cancer

Treatment Algorithm in mCRC: How to Select First-Line Therapy?

Treatment Algorithm in mCRC: Later Lines

Adjuvant Treatment for Stage II-III Colon Cancer

 

Session XIII: New Breakthroughs in Rare Cancers

What is New in GIST in the Last 12 Months?

What is New in Pancreatic NETs in the Last 12 Months?

What is New in Non-Pancreatic NETs in the Last 12 Months?

What is New on Debulking and HIPEC in Peritoneal Carcinomatosis in the Last 12 Months?